OXB.L Stock - Oxford Biomedica plc
Unlock GoAI Insights for OXB.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $128.80M | $89.54M | $139.99M | $142.80M | $87.73M |
| Gross Profit | $53.02M | $39.73M | $69.18M | $82.64M | $46.07M |
| Gross Margin | 41.2% | 44.4% | 49.4% | 57.9% | 52.5% |
| Operating Income | $-39,375,000 | $-184,174,000 | $-30,220,000 | $20.77M | $-5,694,000 |
| Net Income | $-43,190,000 | $-157,490,000 | $-39,157,000 | $19.01M | $-6,245,000 |
| Net Margin | -33.5% | -175.9% | -28.0% | 13.3% | -7.1% |
| EPS | $-0.42 | $-1.63 | $-0.41 | $0.23 | $-0.08 |
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Visit WebsiteEarnings History & Surprises
OXB.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 7, 2026 | — | — | — | — |
Q2 2025 | Apr 9, 2025 | $-0.08 | $-0.10 | -31.2% | ✗ MISS |
Q3 2024 | Sep 23, 2024 | $-0.28 | $-0.31 | -9.5% | ✗ MISS |
Q2 2024 | Apr 29, 2024 | $-0.49 | $-1.13 | -130.5% | ✗ MISS |
Q3 2023 | Sep 20, 2023 | $-0.36 | $-0.50 | -38.8% | ✗ MISS |
Q2 2023 | Apr 25, 2023 | $-0.07 | $-0.14 | -113.9% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $-0.10 | $-0.27 | -161.8% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $0.08 | $0.01 | -89.6% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $0.06 | $0.21 | +256.0% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | $-0.00 | $0.01 | +275.7% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | $-0.04 | $-0.09 | -112.0% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | $-0.07 | $-0.08 | -7.8% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $-0.15 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.03 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.08 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.09 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.05 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.13 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.18 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.13 | — | — |
Latest News
Frequently Asked Questions about OXB.L
What is OXB.L's current stock price?
What is the analyst price target for OXB.L?
What sector is Oxford Biomedica plc in?
What is OXB.L's market cap?
Does OXB.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OXB.L for comparison